{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:59:19Z","timestamp":1791575959782,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112987","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T11:44:44Z","timestamp":1689075884000},"page":"112987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours"],"prefix":"10.1016","volume":"191","author":[{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behbood","family":"Sadrolhefazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristell","family":"Marzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-9163","authenticated-orcid":false,"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.112987_bib1","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2023.112987_bib2","first-page":"1628","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin\u00a0Cancer Res"},{"key":"10.1016\/j.ejca.2023.112987_bib3","first-page":"728","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol\u00a0Cell"},{"key":"10.1016\/j.ejca.2023.112987_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2023.112987_bib5","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller","year":"2011","journal-title":"Expert Rev\u00a0Mol\u00a0Med"},{"key":"10.1016\/j.ejca.2023.112987_bib6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2023.112987_bib7","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc\u00a0Natl\u00a0Acad\u00a0Sci USA"},{"key":"10.1016\/j.ejca.2023.112987_bib8","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2023.112987_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2023.112987_bib10","first-page":"6183","article-title":"Efficacy of BET bromodomain inhibition in Kras-mutant non\u2013small cell lung cancer","volume":"19","author":"Shimamura","year":"2013","journal-title":"Clin\u00a0Cancer Res"},{"key":"10.1016\/j.ejca.2023.112987_bib11","first-page":"577","article-title":"Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic","volume":"127","author":"Tontsch-Grunt","year":"2022","journal-title":"Br\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.112987_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.canlet.2018.02.018","article-title":"Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo","volume":"421","author":"Tontsch-Grunt","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2023.112987_bib13","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/s41388-018-0150-2","article-title":"The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML","volume":"37","author":"Gerlach","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2023.112987_bib14","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1158\/1538-7445.AM2019-5194","article-title":"Abstract 5194: epigenomic and transcriptional profiling of CRC cell lines with distinct response patterns to the BET inhibitor BI 894999","volume":"79","author":"Savarese","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.112987_bib15","first-page":"196","article-title":"Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies","volume":"50","author":"Stathis","year":"2014","journal-title":"Eur\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.112987_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","article-title":"BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study","volume":"126","author":"Abramson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2023.112987_bib17","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2023.112987_bib18","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2023.112987_bib19","article-title":"A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I\/II open label single agent study in patients with acute myeloid leukemia (AML)","author":"Dawson","year":"2017","journal-title":"59th Annual Meeting of the American Society of Hematology (ASH). Atlanta, GA, USA"},{"key":"10.1016\/j.ejca.2023.112987_bib20","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2023.112987_bib21","first-page":"1135","article-title":"Highly-sensitive troponin I is increased in patients with gynecological cancers","volume":"46","author":"Danese","year":"2013","journal-title":"Clin\u00a0Biochem"},{"key":"10.1016\/j.ejca.2023.112987_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1749-8090-1-37","article-title":"Detected troponin elevation is associated with high early mortality after lung resection for cancer","volume":"1","author":"Lim","year":"2006","journal-title":"J\u00a0Cardiothorac\u00a0Surg"},{"key":"10.1016\/j.ejca.2023.112987_bib23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ejca.2023.112987_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1535-7163.MCT-16-0475","article-title":"HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues","volume":"16","author":"Lin","year":"2017","journal-title":"Mol\u00a0Cancer Ther"},{"key":"10.1016\/j.ejca.2023.112987_bib25","article-title":"Cancer cell CCR2 orchestrates suppression of the adaptive immune response","volume":"217","author":"Fein","year":"2020","journal-title":"J\u00a0Exp\u00a0Med"},{"key":"10.1016\/j.ejca.2023.112987_bib26","article-title":"HIST2H2BF potentiates the propagation of cancer stem cells via notch signaling to promote malignancy and liver metastasis in colorectal carcinoma","volume":"11","author":"Qiu","year":"2021","journal-title":"Front\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112987_bib27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/bioinformatics\/btz647","article-title":"NACHO: an R package for quality control of NanoString nCounter data","volume":"36","author":"Canouil","year":"2020","journal-title":"Bioinform"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:37Z","timestamp":1760733757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"alternative-id":["S0959804923003398"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112987","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112987"}}